{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:43:18Z","timestamp":1789706598611,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-022-01262-1","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T12:04:18Z","timestamp":1668081858000},"page":"1996-2010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial"],"prefix":"10.1038","volume":"7","author":[{"given":"Youyi","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-9117","authenticated-orcid":false,"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-8343","authenticated-orcid":false,"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Stieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Le Gars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet A.","family":"Van Roey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obrimpong","family":"Amoa-Awua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mursal","family":"Naisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Narpala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Serebryannyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8045-1754","authenticated-orcid":false,"given":"Mike","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-8090","authenticated-orcid":false,"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Luedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Hyrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars W. P.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-2789","authenticated-orcid":false,"given":"Nima S.","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-0953","authenticated-orcid":false,"given":"Marco","family":"Carone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9004-5154","authenticated-orcid":false,"given":"Leonardo","family":"Paiva de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebone","family":"Maboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-3734","authenticated-orcid":false,"given":"April K.","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Truyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-0260","authenticated-orcid":false,"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-2266","authenticated-orcid":false,"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-5729","authenticated-orcid":false,"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2714","authenticated-orcid":false,"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-0393","authenticated-orcid":false,"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-9427","authenticated-orcid":false,"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Immune Assays Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Coronavirus Vaccine Prevention Network (CoVPN)\/ENSEMBLE Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the United States Government (USG)\/CoVPN Biostatistics Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"1262_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMoa2117608","volume":"386","author":"J Sadoff","year":"2022","unstructured":"Sadoff, J. et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N. Engl. J. Med. 386, 847\u2013860 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR3","unstructured":"Janssen COVID-19 Vaccine (US Food and Drug Administration, accessed 23 January 2022); https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine"},{"key":"1262_CR4","unstructured":"COVID-19 Vaccines WHO EUL Issued (World Health Organization, accessed 24 January, 2022); https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued"},{"key":"1262_CR5","unstructured":"European Commission Authorises Fourth Safe and Effective Vaccine Against COVID-19 (European Commission, accessed 24 January 2022); https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_21_1085"},{"key":"1262_CR6","unstructured":"COVID19 Vaccine Tracker (VIPER Group COVID19 Vaccine Tracker Team, accessed 10 June 2022); https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/"},{"key":"1262_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1262_CR8","unstructured":"Plotkin, S. A. & Gilbert, P. B. in Plotkin\u2019s Vaccines 7th edn (eds Plotkin, S. A. et al.) Ch. 3 (Elsevier, 2018)."},{"key":"1262_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"1262_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","volume":"386","author":"EB Walter","year":"2022","unstructured":"Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 386, 35\u201346 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR11","unstructured":"FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age (US Food and Drug Administration, accessed 3 February 2022); https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age"},{"key":"1262_CR12","doi-asserted-by":"publisher","first-page":"ofab632","DOI":"10.1093\/ofid\/ofab632","volume":"9","author":"N Duarte","year":"2022","unstructured":"Duarte, N. et al. Adapting serosurveys for the SARS-CoV-2 vaccine era. Open Forum Infect. Dis. 9, ofab632 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"1262_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2034545","volume":"384","author":"SF Lumley","year":"2021","unstructured":"Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533\u2013540 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR14","doi-asserted-by":"crossref","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 58, 2020.","DOI":"10.1128\/JCM.02107-20"},{"key":"1262_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"1262_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"1262_CR17","doi-asserted-by":"publisher","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","volume":"373","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 (2021).","journal-title":"Science"},{"key":"1262_CR18","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","volume":"184","author":"X He","year":"2021","unstructured":"He, X. et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell 184, 3467\u20133473.e11 (2021).","journal-title":"Cell"},{"key":"1262_CR19","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med. 385, 1184\u20131195 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"1262_CR21","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"1262_CR22","doi-asserted-by":"crossref","unstructured":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation, Krause, P. R. et al. Placebo-controlled trials of Covid-19 vaccines - why we still need them. N. Engl. J. Med. 384, e2 (2021).","DOI":"10.1056\/NEJMp2033538"},{"key":"1262_CR23","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41591-021-01484-6","volume":"27","author":"RA Koup","year":"2021","unstructured":"Koup, R. A. et al. A government-led effort to identify correlates of protection for COVID-19 vaccines. Nat. Med. 27, 1493\u20131494 (2021).","journal-title":"Nat. Med."},{"key":"1262_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"1262_CR26","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"1262_CR27","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science."},{"key":"1262_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1262_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"1262_CR30","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"1262_CR31","doi-asserted-by":"crossref","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022.","DOI":"10.1111\/imr.13091"},{"key":"1262_CR32","unstructured":"Interim Statement on Hybrid Immunity and Increasing Population Seroprevalence Rates (WHO, accessed 8 September 2022); https:\/\/www.who.int\/news\/item\/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates"},{"key":"1262_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMc2108829","volume":"385","author":"DH Barouch","year":"2021","unstructured":"Barouch, D. H. et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N. Engl. J. Med. 385, 951\u2013953 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1262_CR34","doi-asserted-by":"crossref","unstructured":"Pajon, R. et al. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat. Med. 2022.","DOI":"10.1101\/2021.09.28.21264252"},{"key":"1262_CR35","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451.e17 (2022).","journal-title":"Cell"},{"key":"1262_CR36","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.xcrm.2022.100510","volume":"3","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep. Med. 3, 100510 (2022).","journal-title":"Cell Rep. Med."},{"key":"1262_CR37","doi-asserted-by":"crossref","unstructured":"Sadoff, J. et al. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials. Vaccine 2022.","DOI":"10.1016\/j.vaccine.2022.05.047"},{"key":"1262_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","volume":"596","author":"G Alter","year":"2021","unstructured":"Alter, G. et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature 596, 268\u2013272 (2021).","journal-title":"Nature"},{"key":"1262_CR39","unstructured":"Instructions for Use of First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC code: 20\/136 (National Institute for Biological Standards and Control, accessed 29 July 2021); https:\/\/www.nibsc.org\/science_and_research\/idd\/cfar\/covid-19_reagents.aspx"},{"key":"1262_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03154-6","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921 (2021).","journal-title":"Sci. Rep."},{"key":"1262_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/biomet\/73.1.1","volume":"73","author":"RL Prentice","year":"1986","unstructured":"Prentice, R. L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73, 1\u201311 (1986).","journal-title":"Biometrika"},{"key":"1262_CR42","doi-asserted-by":"crossref","unstructured":"Lumley, T. Complex Surveys: A Guide to Analysis Using R Vol. 565 (John Wiley & Sons, 2010).","DOI":"10.1002\/9780470580066"},{"key":"1262_CR43","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2022)."},{"key":"1262_CR44","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B., Fong, Y., Kenny, A. & Carone, M. A controlled effects approach to assessing immune correlates of protection. Biostatistics https:\/\/doi.org\/10.1093\/biostatistics\/kxac24 (2022).","DOI":"10.1093\/biostatistics\/kxac24"},{"key":"1262_CR45","unstructured":"van der Laan, L., Zhang, W. & Gilbert, P. B. Efficient nonparametric estimation of the covariate-adjusted threshold-response function, a support-restricted stochastic intervention. Preprint at https:\/\/arxiv.org\/abs\/2107.11459 (2021)."},{"key":"1262_CR46","unstructured":"Westfall, P. H. & Young, S. S. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment Vol. 279, Wiley Series in Probability and Statistics (John Wiley & Sons, 1993)."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01262-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:05:14Z","timestamp":1717488314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01262-1","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, the Statistical Analysis Plan was missing from the Supplementary information and has now been uploaded online.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      and declare that: P.B.G., Y.F., D.B., A.L., O.H., Y.L., C.Y., B.B., L.W.P.v.d.L., A.K., M.C., A.K.R., M.P.A., J.G.K., L.C. and L.N.C. had support (in the form of grant payments to their respective institutions) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health for the submitted work; O.A.-A. had support from the NIH Vaccine Immunology Program for the submitted work; C.J.P. had support from Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) for the contract testing provided by Labcorp-Monogram Biosciences for the submitted work and is a shareholder in and corporate officer of Labcorp; A.L. declares support (in the form of grant payments to his institution) within the past 36 months from Janssen Pharmaceuticals for work on the HVTN 706 HIV vaccine efficacy trial and from the World Health Organization for writing the statistical analysis plan for the WHO\u2019s Solidarity Trial for COVID-19 vaccines, as well as consulting fees within the past 36 months received from Harvard Medical School for statistical consulting on individualized medicine software; O.H. had support (in the form of payments to his institution) from the Bill and Melinda Gates Foundation within the past 36 months; N.S.H. had support (in the form of payments to his institution) from the National Science Foundation for the submitted work; S.R., D.J.S. and G.A.V.R. had partial support from the Department of Health and Human Services BARDA (in the form of contract payments to their respective institution) for the submitted work, has stock and\/or stock options in Johnson & Johnson, and are employees of Janssen; A.V. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, had all patent rights transferred to Johnson & Johnson, has stock and\/or stock options in Johnson & Johnson, and is an employee of Janssen; M.L.G. had partial support from BARDA (in the form of contract payments to his institution) for the submitted work, has shares in Johnson & Johnson, and is an employee of Johnson & Johnson; M.C. declares an honorarium from Pfizer within the past 36 months for serving on a scientific panel to evaluate submitted funding proposals on use of talazoparib in prostate cancer, submitted in response to a joint call by the National Comprehensive Cancer Network and Pfizer; J.S. declares support for the submitted work from the Janssen Pharmaceutical Companies of Johnson & Johnson and partial support (in the form of funding to his institution) from BARDA for the submitted work, declares support within the past 36 months from the Janssen Pharmaceutical Companies of Johnson & Johnson and BARDA funding for part of this work, has patents on invention of the Janssen COVID-19 vaccine, and has Johnson & Johnson stock and stock options; G.E.G. declares payment for speaking at a Johnson & Johnson-sponsored session at a conference within the past 36 months (payment donated to charity) and for serving on the Johnson & Johnson COVID-19 Vaccine Advisory Board (fees donated to charity), as well as receipt of 500,000 doses of Ad26.COV2.S vaccine donated by the United States Government\/Johnson & Johnson for the Sisonke study; B.G. received consulting fees from Janssen within the past 36 months and declares receiving payments from Merck, Janssen and GSK within the last 36 months for participation on advisory boards, as well as receipt of Truvada provided to her institution from Gilead within the past 36 months for a PrEP demonstration project; P.A.G. declares support (in the form of grant payments to his institution) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health within the past 36 months and consulting fees from Johnson & Johnson in the past 36 months; J.H. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, is a shareholder of Janssen Pharmaceuticals, and is an employee of Janssen Pharmaceuticals, C.T. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, holds stock in Janssen Pharmaceuticals, and is an employee of Janssen Pharmaceuticals; F.S. had partial support from BARDA (in the form of contract payments to his institution) for the submitted work, has restricted shares in Johnson & Johnson as part of compensation for employment, has shares in GlaxoSmithKline as compensation for past employment, and is employed by Johnson & Johnson; H.S. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, is a holder of Johnson & Johnson stock, and is an employee of Janssen Vaccines & Prevention BV; M.D. had partial support from BARDA (in the form of contract payments to her institution) for the submitted work, is a shareholder of Johnson & Johnson stock (has Johnson & Johnson Company stocks and stock options), and is an employee of Johnson & Johnson; K.M.N. declares grants paid to her institution within the past 36 months from Pfizer to conduct clinical trials of COVID vaccines (no salary support received from this grant) and support (in the form of grant payments to her institution) within the past 36 months from the National Institutes of Health; P.B.G. is a member of the BMGF COVID-19 Correlates Working Group (unpaid\/no compensation); R.A.K. had support (in the form of intramural funding from NIAID) for the submitted work; R.O.D. declares that BARDA provided funding to Janssen and to Monogram Biosciences for the submitted work. All other authors declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The COV3001 (ENSEMBLE) study was reviewed and approved by the following local ethics committees and Institutional Review Boards (IRBs): <b>Argentina:<\/b> ANMAT - Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnologia M\u00e9dica (Capital Federal, La Plata, Ramos Mejia \u2013 Buenos Aires; Ciudad Autonoma de Buenos Aires), Comite de Etica Dr Carlos Barclay (Capital Federal, Buenos Aires; Ciudad Autonoma de Buenos Aires), Comision Conjunta de Investigacion en Salud \u2013 CCIS (La Plata, Ramos Mejia \u2013 Buenos Aires), Comite de Bioetica de Fundacion Huesped (Ciudad Autonoma de Buenos Aires), Comit\u00e9 de Docencia e Investigaci\u00f3n DIM Cl\u00ednica Privada (Ramos Mejia, Buenos Aires), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Cl\u00ednica y Maternidad Suizo Argentina (Ciudad Autonoma de Buenos Aires), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n de CEMIC (Ciudad Autonoma de Buenos Aires), Comite de Etica en Investigacion DIM Clinica Privada (Ramos Mejia, Buenos Aires), Comite de Etica Hospital Italiano de La Plata (La Plata, Buenos Aires), Comite de Etiica en Investigacion Hospital General de Agudos J.M. Ramos Mejia (Ciudad Autonoma de Buenos Aires), Comit\u00e9de \u00e9tica del Instituto M\u00e9dico Platense (CEDIMP) (La Plata, Buenos Aires), Institutional Biosafety Committee (IBC) Fundacion Huesped (Ciudad Autonoma de Buenos Aires), IBC Helios Salud (Ciudad Autonoma de Buenos Aires) and IBC Hospital General de Agudos J.M. Ramos Mejia (Ciudad Autonoma de Buenos Aires). <b>Brazil:<\/b> ANVISA \u2013 Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Salvador, Bahia; Barretos, Campinas, S\u00e3o Paulo, S\u00e3o Jose Rio Preto, Ribeir\u00e3o Preto, S\u00e3o Caetano do Sul \u2013 S\u00e3o Paulo; Santa Maria, Porto Alegre \u2013 Rio Grande do Sul; Natal, Rio Grande do Norte; Para, Par\u00e1; Belo Horizonte, Minas Gerais; Rio de Janeiro, Nova Igua\u00e7u \u2013 Rio de Janeiro; Curitiba, Paran\u00e1; Bras\u00edlia, Distrito Federal; Campo Grande, Mato Grosso do Sul; Crici\u00fama, Santa Catarina; Cuiab\u00e1, Mato Grosso), CONEP - Comiss\u00e3o Nacional de \u00c9tica em Pesquisa (Salvador, Bahia; S\u00e3o Paulo, S\u00e3o Paulo; Santa Maria, Rio Grande do Sul; Para, Par\u00e1;), CAPPESq \u2013 Comiss\u00e3o de \u00c9tica de An\u00e1lise para Projetos de Pesquisa \u2013 HCFMUSP (S\u00e3o Paulo, S\u00e3o Paulo), CEP da Faculdade de Medicina de S\u00e3o Jos\u00e9 do Rio Preto \u2013 FAMERP (S\u00e3o Jose Rio Preto, S\u00e3o Paulo), CEP da Faculdade de Medicina do ABC\/SP (S\u00e3o Paulo, S\u00e3o Paulo), CEP da Funda\u00e7\u00e3o Pio XII - Hospital do C\u00e2ncer de Barretos\/SP (Barretos, S\u00e3o Paulo), CEP da Liga Norteriograndense Contra o C\u00e2ncer (Natal, Rio Grande do Norte), CEP da Pontificia Universidade Catolica de Campinas \/ PUC Campinas (Campinas, S\u00e3o Paulo), CEP da Real Benem\u00e9rita Associa\u00e7ao Portuguesa de Benefic\u00eancia - Hospital S\u00e3o Joaquim (S\u00e3o Paulo, S\u00e3o Paulo), CEP da Santa Casa de Miseric\u00f3rdia de Belo Horizonte (Belo Horizonte, Minas Gerais), CEP da Secretaria Municipal De Sa\u00fade do Rio de Janeiro \u2013 SMS\/RJ (Rio de Janeiro, Rio de Janeiro), CEP da Universidade de S\u00e3o Caetano do Sul (CEP da Universidade de S\u00e3o Caetano do Sul, S\u00e3o Paulo), CEP da Universidade Federal de Mato Grosso do Sul \u2013 UFMS (Campo Grande, Mato Grosso do Sul), CEP da Universidade Federal de Minas Gerais (Belo Horizonte, Minas Gerais), CEP do Centro de Refer\u00eancia e Treinamento DST\/AIDS (S\u00e3o Paulo, S\u00e3o Paulo), CEP do do INI-Ipec\/Fiocruz (Rio de Janeiro, Rio de Janeiro), CEP do Grupo Hospitalar Concei\u00e7\u00e3o \/ RS (Porto Alegre, Rio Grande do Sul), CEP do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto\/USP (Ribeir\u00e3o Preto, S\u00e3o Paulo), CEP do Hospital de Clinicas da Universidade Federal do Parana - HCUFPR \/ PR (Curitiba, Paran\u00e1), CEP do Hospital de Cl\u00ednicas de Porto Alegre\/HCPA (Porto Alegre, Rio Grande do Sul), CEP do Hospital Geral de Nova Igua\u00e7u (Nova Igua\u00e7u, Rio do Janeiro), CEP do Hospital Municipal S\u00e3o Jos\u00e9 (Crici\u00fama, Santa Catarina), CEP do Hospital Pr\u00f3-Card\u00edaco\/RJ (Rio de Janeiro, Rio de Janeiro), CEP do Hospital S\u00edrio Liban\u00eas (S\u00e3o Paulo, Sao Paulo), CEP do Hospital Universit\u00e1rio J\u00falio Muller \/ MT (Cuiab\u00e1, Mato Grosso), CEP do Hospital Universit\u00e1rio Professor Edgard Santos \u2013 UFBA (Salvador, Bahia), CEP do Instituto de Cardiologia do Distrito Federal (Bras\u00edlia, Distrito Federal), CEP do Instituto de Infectologia Em\u00edlio Ribas\/SP (S\u00e3o Paulo, Sao Paulo), CEP do Instituto de Saude e Bem Estar da Mulher - ISBEM \/ SP (S\u00e3o Paulo, Sao Paulo), CEP em Seres Humanos do HFSE - Hospital Federal dos Servidores do Estado (Rio de Janeiro, Rio de Janeiro), and CONEP - Comiss\u00e3o Nacional de \u00c9tica em Pesquisa (Bras\u00edlia, Distrito Federal, Salvador, Bahia; Belo Horizonte, Minas Gerais; Cuiab\u00e1, Mato Grosso; Campo Grande, Mato Grosso do Sul; Nova Igua\u00e7u, Rio Janeiro \u2013 Rio Janeiro; Barretos, Campinas, Sao Jose Rio Preto, S\u00e3o Caetano do Sul, Sao Paulo, Ribeir\u00e3o Preto \u2013 Sao Paulo; Porto Alegre, Rio Grande do Sul; Natal, Rio Grande do Norte; Curitiba, Paran\u00e1; and Crici\u00fama, Santa Catarina). <b>Chile:<\/b> Comit\u00e9 de \u00c9tica de Investigaci\u00f3n en Seres Humanos (Santiago, Region Met), Comit\u00e9 \u00c9tico Cient\u00edfico Servicio de Salud Metropolitano Central (Santiago, Region Met), Instituto de Salud P\u00fablica de Chile (Santiago, Region Met; Talca, Temuco), Comit\u00e9 \u00c9tico Cient\u00edfico Servicio de Salud Metropolitano Sur Oriente (Talca, Santiago), Comit\u00e9 de Evaluaci\u00f3n \u00c9tica Cient\u00edfica Servicio de Salud Araucan\u00eda Sur Temuco (Temuco) and Comit\u00e9 \u00c9tico Cient\u00edfico Servicio de Salud Metropolitano Central (Vi\u00f1a del Mar). <b>Colombia:<\/b> CEI de la Fundaci\u00f3n Cardiovascular de Colombia (Floridablanca), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Cl\u00ednica de la Costa (Barranquilla), INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Barranquilla), Comite de Etica en Investigacion de la E.S.E. Hospital Mental de Antioquia (Santa Marta), Comite de Etica en la Investigacion CAIMED (Bogot\u00e1), INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Bogot\u00e1), Comite Corporativo de Etica en Investigacion de la Fundacion Santa Fe de Bogota (Bogot\u00e1), Comit\u00e9 de \u00c9tica e Investigaci\u00f3n Biom\u00e9dica de la Fundaci\u00f3n Valle del Lili (Cali), Comite de Etica e Investigacion IPS Universitaria (Medellin), Comite de Etica en Investigacion Asustencial Cientifica de Alta Complejidad (Bogot\u00e1), Comite de Etica en Investigacion Biomedica de la Corporacion Cientifica Pediatrica de Cali (Cali), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Cl\u00ednica de la Costa (Barranquilla), Comite de Etica en Investigacion de la E.S.E. Hospital Mental de Antioquia (Barrio Barzal Villavicencio), Comite de Etica en Investigacion del area de la Salud de la Universidad del Norte (Barranquilla), Comite de Etica en Investigacion Medplus Centro de Recuperaci\u00f3n Integral S.A.S (Bogot\u00e1), Comit\u00e9 de \u00c9tica en Investigaciones CEI-FOSCAL (Floridablanca), Comite de Etica en la Investigacion CAIMED (Bogot\u00e1), Comite de Etica para Investigacion Clinica(CEIC) de la Fundacion Centro de Investigacion Clinica CIC (Medellin) and Comite de Investigaciones y Etica en Investigaciones Hospital Pablo Tobon Uribe (Medellin), and INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Barranquilla, Bogot\u00e1, Cali, Floridablanca, Medellin). <b>Mexico:<\/b> CEI del Hospital Civil de Guadalajara Fray Antonio Alcalde (Guadalajara, Jalisco), CEI Hospital La Mision (Tijuana, Baja California Norte), CI del Hospital Civil de Guadalajara Fray Antonio Alcalde (Guadalajara, Jalisco), CI Hospital La Mision (Tijuana, Baja California Norte), Comite de Bioseguridad del Instituto Nacional de Salud Publica (Mexico, Distrito Federal; Cuernavaca, Morelos), Comite de Etica en Investigacion del Instituto Nacional de Salud Publica (Mexico, Distrito Federal; Cuernavaca, Morelos), Comit\u00e9 de Bioseguridad del Hospital La Misi\u00f3n S.A. de C.V. (Tijuana, Baja California Norte; Oaxaca, Oaxaca; Merida, Yucat\u00e1n; Tijuana, Baja California Norte), Comit\u00e9 de Bioseguridad de la Coordinaci\u00f3n de Investigaci\u00f3n en Salud (IMSS) (Mexico, Estado de Mexico), Comit\u00e9 de Bioseguridad de M\u00e9dica Rio Mayo (CLINBOR) (Mexico, Distrito Federal), Comit\u00e9 de Bioseguridad del Hospital Universitario \u2018Dr Jos\u00e9 Eleuterio Gonz\u00e1lez\u2019 (Monterrey, Nuevo Le\u00f3n), COFEPRIS (Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios) (Cuernavaca, Morelos; Mexico, Distrito Federal; Monterrey, Nuevo Le\u00f3n; Oaxaca, Oaxaca; Merida, Yucat\u00e1n), Comite de Etica de la Fac de Med de la UANL y Hospital Universitario \u2018Dr Jose Eleuterio Gonzalez\u2019 (Monterrey, Nuevo Le\u00f3n), Comite de Etica en Investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C. (Merida, Yucat\u00e1n), Comite de Etica en Investigacion de Medica Rio Mayo S.C. (Mexico, Distrito Federal), Comite de Etica en Investigacion de Oaxaca Site Management Organization, S.C. (Oaxaca, Oaxaca), Comite de Etica en Investigacion del Centro Medico Nacional Siglo XXI (IMSS) (Mexico, Estado do Mexico), Comit\u00e9 de Investigaci\u00f3n de la Coordinaci\u00f3n de Investigaci\u00f3n en Salud (IMSS) (Mexico, Estado do Mexico), Comite de Investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C. (Merida, Yucat\u00e1n), Comite de Investigacion de Oaxaca Site Management Organization, S.C. (Oaxaca, Oaxaca), Comit\u00e9 de Investigaci\u00f3n del Hospital Universitario Jos\u00e9 Eleuterio Gonz\u00e1lez (Monterrey, Nuevo Le\u00f3n) and Comite de Investigacion Medica Rio Mayo, S.C. (Mexico, Distrito Federal). <b>Peru:<\/b> Comite Nacional Transitorio de Etica en Invest. de los Ensayos Clinicos de la enfermedad COVID-19 (Iquitos \u2013 Maynas, Loreto; Lima, San Miguel \u2013 Lima) and INS - Instituto Nacional de Salud (Peru) (Lima, San Miguel \u2013 Lima; Callao; Iquitos \u2013 Maynas, Loreto). <b>South Africa:<\/b> Department Agriculture, Forestry and Fisheries (DAFF) (Port Elizabeth, Mthatha \u2013 Eastern Cape; Cape Town, Worcester \u2013 Western Cape; Durban, Ladysmith, Vulindlela \u2013 KwaZulu-Natal; Johannesburg, Pretoria, Mamelodi East, Soweto, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), Pharma Ethics (Port Elizabeth, Eastern Cape; Durban, Ladysmith \u2013 KwaZulu-Natal; Cape Town, Western Cape; Pretoria, Mamelodi East, Johannesburg, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), SAHPRA - South African Health Products Regulatory Authority (Port Elizabeth, Mthatha \u2013 Eastern Cape; Cape Town, Worcester \u2013 Western Cape; Durban, Ladysmith, Vulindlela \u2013 KwaZulu-Natal; Johannesburg, Pretoria, Mamelodi East, Soweto, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), WIRB (Mamelodi East, Pretoria \u2013 Gauteng; Ladysmith, KwaZulu-Natal; Bloemfontein, Free State; Cape Town, Western Cape; Dennilton, Limpopo), Wits Health Consortium (Soweto, Johannesburg \u2013 Gauteng; Ladysmith, KwaZulu-Natal; Mthatha, Eastern Cape), Wits IBC (Soweto, Pretoria, Johannesburg, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Mthatha, Eastern Cape), University of Cape Town HREC (Cape Town, Worcester \u2013 Western Cape); University of Cape Town Institute of Infectious Disease and Molecular Medicine (Cape Town, Worcester \u2013 Western Cape), University of Cape Town IBC (Cape Town, Worcester \u2013 Western Cape), SAMRC Human Research Ethics Committee Scientific Review (Durban, KwaZulu-Natal), Sefako Makgatho University Research Ethics Committee (SMUREC) (Pretoria, Gauteng), University of KwaZulu-Natal IBC (Durban, KwaZulu-Natal), University of KwaZulu-Natal Ethics (Durban, Vulindlela \u2013 KwaZulu-Natal), University of Stellenbosch Ethics Committee (Cape Town, Western Cape) and University of KwaZulu-Natal IBC (Vulindlela, KwaZulu-Natal). <b>United States:<\/b> Advarra IBC (Detroit, MI; Chapel Hill, NC; Boston, MA; Seattle, WA; Winston-Salem, NC; Austin, TX; Peoria, IL; Huntsville, AL; Long Beach, CA; Tucson, AZ), Biomedical Institute of New Mexico IBC (Albuquerque, NM), Birmingham VA Medical Center \u2013 Alabama IBC (Birmingham, AL), Clinical Biosafety Services (Hollywood, FL), Columbia University IBC (New York, NY), Copernicus Group IRB (Austin, Dallas, Houston, San Antonio \u2013 TX; Rochester, New York, Bronx, Binghamton \u2013 NY; Hillsborough, Hackensack, Newark, New Brunswick \u2013 NJ; West Palm Beach, Coral Gables, Hollywood, Miami, Orlando, Gainesville, Tampa, Hallandale Beach, Pinellas Park, The Villages, Jacksonville, Deland \u2013 FL; Fort Worth, Dallas, San Antonio \u2013 TX; Norfolk, Charlottesville \u2013 VA; Matairie, New Orleans \u2013 LA; Nashville, Knoxville, Memphis, Bristol \u2013 TN; Cincinnati, Cleveland, Columbus, Akron \u2013 OH; Detroit, Ann Arbor, Grand Rapids \u2013 MI; Philadelphia, Pittsburgh \u2013 PA; Stanford, San Diego, San Francisco, Oakland, Long Beach, Anaheim, Sacramento, West Hollywood \u2013 CA, Las Vegas, Reno \u2013 NV; Chicago, Peoria \u2013 IL; Omaha, NE; Mobile, Birmingham, Huntsville \u2013 AL; St Louis, Greer, Kansas City \u2013 MO; Boston, MA; Harrisburg, SD; Decatur, Atlanta, Savannah \u2013 GA; Baltimore, Rockville, Annapolis \u2013 MD; New Haven, Hartford \u2013 CT; Chapel Hill, Raleigh, Fayetteville, Charlotte, Durham, Winston-Salem \u2013 NC; Indianapolis, Valparaiso, Evansville \u2013 IN; Seattle, WA; Aurora, CO; Lexington, Louisville \u2013 KY; Murray, West Jordan, Salt Lake City \u2013 UT; Phoenix, Tucson, Glendale \u2013 AZ; Spartanburg, Columbia, North Charleston, Anderson, Charleston, Mount Pleasant \u2013 SC; Portland, Medford, Corvallis \u2013 OR; Albuquerque, Gallup \u2013 NM; Little Rock, AR; Jackson, MS; Newport News, VA, Minneapolis, MN; Lenexa, KS), WIRB (Hackensack, NJ; Dallas, TX; Baltimore, MD; Chicago, IL; Aurora, CO; Winston-Salem, NC; Minneapolis, MN; Orlando, Miami, Gainesville \u2013 FL; Philadelphia, Pittsburgh \u2013 PA; Boston, MA; St Louis, MO; Bronx, New York, NY; New Brunswick, NJ; Phoenix, AZ; Birmingham, AL; Louisville, KY; Albuquerque, NM; New Orleans, LA; Baltimore, MD; San Francisco, CA; Tampa, FL; Aurora, CO; Columbia, SC; Decatur, GA; Reno, NV; Raleigh, NC; Little Rock, AS), Clinical Biosafety Services (Dallas, San Antonio \u2013 TX; San Diego, CA; Lexington, KY; Murray, UT; Greer, Kansas City, St Louis \u2013 MO; Rockville, MD; Las Vegas, NV; Cincinnati, Columbus, Akron \u2013 OH; Phoenix, Tucson, Glendale \u2013 AZ; North Charleston, Anderson \u2013 SC; Orlando, Pinellas Park, The Villages, Miami \u2013 FL; Birmingham, AL; Valparaiso, Evansville \u2013 IN; Lenexa, KS), Columbia University IBC (Bronx, New York), Durham VA Medical Center IBC (Raleigh, NC), Emory University IRB (Decatur, GA), Environmental Health and Safety Office (Atlanta, GA), IBC (New Orleans, LA), James A. Haley Veterans Hospital IBC (Tampa, FL), Jesse Brown VA Medical Center IBC (Chicago, IL), Mass General Brigham IBC (Boston, MA), Mount Sinai- Icahn School of Medicine IBC (New York, NY), New York Blood Center IBC (New York, NY), OHSU IBC (Portland, OR), Partners IBC (Boston, MA), Rocky Mountain Regional VA Medical Center IBC (Aurora, CO), Rush University Medical Center (Chicago, IL), Rush University Medical Center IBC (Chicago, IL), Rutgers IBC (New Brunswick, NJ), Saint Louis University IBC (St Louis, MO), Saint Michael\u2019s Medical Center IRB (Newark, NJ), Southeast Louisiana Veterans Health Care System IBC (New Orleans, LA), St. Jude Children\u2019s Research Hospital IBC Committee (Memphis, TN), St. Jude Children\u2019s Research Hospital IRB (Memphis, TN), Stanford University Administrative Panel on Human Subjects in Medical Research (Stanford, CA), Temple University IBC (Philadelphia, PA), The University of Chicago IBC (Chicago, IL), UAMS IBC (Little Rock, AS), UIC IBC (Chicago, IL), University of Alabama at Birmingham IBC (Birmingham, AL), University of Arkansas IRB (Little Rock, AS), University of Kentucky Biological Safety (Lexington, KY), University of Kentucky IRB (Lexington, KY), University of Louisville IRB (Louisville, KY), University of Miami IBC (Miami, FL), University of Mississippi Medical Center IRB (Jackson, MI), University of Pennsylvania IBC (Philadelphia, PA), University of Pittsburgh IBC (Pittsburgh, Pennsylvania), University of South Florida IRB (Tampa, FL), University of Utah IBC (Salt Lake City, UT), University of Utah IRB (Salt Lake City, UT), UTHealth IBC (Houston, TX), VA Baltimore Research and Education Foundation (BREF) IBC (Baltimore, MD), VA Central Arkansas Veterans Healthcare System IBC (Little Rock, AS), VA James J. Peters Department of VA Medical Center IBC (Bronx, NY), VA Medical Center \u2013 Atlanta IBC (Decatur, GA), VA Medical Center San Francisco IBC (San Francisco, CA), VA North Florida\/South Georgia IBC (Gainesville, FL), VA North Texas Health Care System IBC (Dallas, TX), VA San Diego Healthcare System IBC (Phoenix, AZ), VA Sierra Nevada Health Care System IBC (Reno, NV), Vanderbilt University IRB (Nashville, TN), Washington University IBC (St Louis, MO), WCG IBCS (Houston, TX; Orlando, FL), Western IRB (San Diego, CA; Detroit, MI; New Orleans, LA; New York, NY), WIRB - IBCS Services (Chicago, IL; New Orleans, LA; Oakland, CA; Minneapolis, MN; Columbus, OH; Lexington, KY) and WJB Dorne VA Medical Center IBC (Columbia, SC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics committees"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}